newsfilter
← Latest News
PR Newswire·

Cryoport Reports Fourth Quarter and Full-Year 2025 Financial Results

CYRX
  • Cryoport reported FY 2025 total revenue of $176.2 million, exceeding previous guidance high-end targets.
  • Life Sciences Services revenue grew 18% year-over-year in FY 2025, reaching $96.5 million.
  • BioStorage/BioServices revenue within the Life Sciences Services segment increased 22% year-over-year.
  • Commercial cell and gene therapy revenue rose 29% year-over-year to $33.4 million in FY 2025.
  • The company supported a record 760 global clinical trials as of December 31, 2025.
  • Cryoport supported 20 commercially approved therapies as of December 31, 2025.
  • Life Sciences Products segment revenue increased 7% year-over-year to $79.7 million in FY 2025.
  • Full-year 2026 revenue guidance is set between $190 million and $194 million, reflecting 8%-10% growth.
  • Gross margin for FY 2025 improved to 47.1% from 44.4% in the prior year.
  • Adjusted EBITDA from continuing operations improved by $12 million year-over-year to a negative $5.8 million for FY 2025.
  • Net income for FY 2025 was $78.3 million, driven primarily by the $112.3 million after-tax gain from the CRYOPDP divestiture.
  • The company completed a strategic partnership with DHL Group, including the sale of CRYOPDP, in June 2025.
  • Cash, cash equivalents, and short-term investments totaled $411.2 million as of December 31, 2025.
  • Share repurchase programs in 2025 resulted in the buyback of 1,340,608 shares for an aggregate of $10.0 million.
  • Operational milestones included the launch of a Global Supply Chain Center in Paris, France, 2025.
  • MVE Biological Solutions launched the Fusion 800 Series, a self-sustaining cryogenic freezer, in FY 2025.
  • Cryoport Systems achieved ISO 21973:2020 certification for cell transportation safety in FY 2025.
  • The company anticipates 13 BLA/MAA filings, nine new therapy approvals, and two label expansions in 2026.